DrugBiological
Rituximab clinical trials
Also written Rituxan, Mabthera, IDEC-C2B8 and MK-8808.
Includes 7 studies of Rituximab and Hyaluronidase Human.
Related medicines add 3 studies
Counted the way a researcher would: Rituximab with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Rituximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Rituximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 26 Nov 1997 · RITUXAN · BLA 103705 (FDA, Drugs@FDA)
- European Union
- 2 Jun 1998 · MabThera · EMEA/H/C/000165 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
In one entry with another drug
Given together, or one or the other
Biosimilars
- Rixathon
- 7
- Ruxience
- 2
- ABP 798
- 2
Studies by the year they started
1,270 studies that test it; most in 2006 (82); 2 more planned to start later
| Year | Studies |
|---|---|
| 1993 | 1 |
| 1995 | 2 |
| 1997 | 6 |
| 1998 | 16 |
| 1999 | 18 |
| 2000 | 19 |
| 2001 | 21 |
| 2002 | 32 |
| 2003 | 54 |
| 2004 | 71 |
| 2005 | 76 |
| 2006 | 82 |
| 2007 | 65 |
| 2008 | 59 |
| 2009 | 70 |
| 2010 | 54 |
| 2011 | 52 |
| 2012 | 53 |
| 2013 | 41 |
| 2014 | 38 |
| 2015 | 44 |
| 2016 | 42 |
| 2017 | 26 |
| 2018 | 33 |
| 2019 | 48 |
| 2020 | 45 |
| 2021 | 31 |
| 2022 | 25 |
| 2023 | 49 |
| 2024 | 33 |
| 2025 | 34 |
| 2026 | 30 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 201 · Other 1,082
M.D. Anderson Cancer Center (73) · Hoffmann-La Roche (60) · National Cancer Institute (NCI) (59) · Memorial Sloan Kettering Cancer Center (26) · Mayo Clinic (23) · Assistance Publique - Hôpitaux de Paris (22) · Alliance for Clinical Trials in Oncology (17) · Genentech, Inc. (17)
Often tested with
Tested in the same studies.
Cyclophosphamide (162) · Lenalidomide (95) · Fludarabine (88) · Bendamustine (72) · Prednisone (64) · Vincristine (63) · Bortezomib (60) · Doxorubicin (59)
Related medicines
As reviewed, each with the page that says it.
- One of Immunologic Factors source
- 131I-rituximab is a conjugate made from it, counted on its own page source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 35 phase 3 studies under way
Rituximab is the comparator. A study of two new drugs counts under both.
- 3Mosunetuzumab · The Lymphoma Academic Research Organisation, Hoffmann-La Roche · next primary completion Sep 2027
- 3Acalabrutinib · Acerta Pharma BV, AstraZeneca · next primary completion Aug 2027
- 3Lenalidomide · The Lymphoma Academic Research Organisation, Beijing InnoCare Pharma Tech Co., Ltd. · next primary completion Sep 2027
- 3Odronextamab · Regeneron Pharmaceuticals · next primary completion Feb 2028
- 2Pirtobrutinib · Loxo Oncology, Inc.
- 2Axicabtagene ciloleucel · Kite, A Gilead Company · next primary completion Oct 2030
- 2ARQ531 · Merck Sharp & Dohme LLC · next primary completion May 2027
- 2SCTB35 · Sinocelltech Ltd. · next primary completion Nov 2027
Reaching primary completion within a year · 62, 11 in phase 3
Studies that test Rituximab, phase 3 first.
- Nov 2026Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune ThrombocytopeniaPhase 3 · Assistance Publique - Hôpitaux de Paris
- Jan 2027Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR RelapsePhase 3 · Sint Maartenskliniek
- Jan 2027A Phase III Clinical Trial of High-dose Rituximab (500mg/m²) Combined With CHOP Regimen in the Treatment of Male Patient With Newly Diagnosed Advanced DLBCLPhase 3 · Xia Yi
- Jan 2027Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete RemissionPhase 3 · ECOG-ACRIN Cancer Research Group
- Feb 2027A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.Phase 3 · Epizyme, Inc.
- Mar 2027Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane PemphigoidPhase 3 · University Hospital, Rouen
- Mar 2027A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaPhase 3 · Memorial Sloan Kettering Cancer Center
- May 2027Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MSPhase 3 · Amsterdam UMC, location VUmc
- Jun 2027A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)Phase 3 · Genmab
- Jul 2027Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentPhase 3 · Ruijin Hospital
Studies
Open first, then newest update. How each study uses Rituximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 1,283
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingPhase 2Massachusetts General HospitalNCT06561347Written as Rituximab
- A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06149286Written as Rituximab
- Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular LymphomaRecruitingPhase 3National Cancer Institute (NCI)NCT06337318Written as Rituximab
- Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)RecruitingPhase 2National Center of Neurology and Psychiatry, JapanNCT06952413Written as Rituximab(Genetical Recombination)
- Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) PatientsRecruitingPhase 2M.D. Anderson Cancer CenterNCT06263491Written as Rituximab
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07231952Written as Rituximab
- Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04404088Written as Rituximab
- Personalized NK Cell Therapy in CBTRecruitingPhase 2M.D. Anderson Cancer CenterNCT02727803Written as Rituximab
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective StudyRecruitingPhase 4The First Hospital of Jilin UniversityNCT07908888Written as Rituximab
- Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCLRecruitingPhase 2AstraZenecaNCT05952024Written as Rituximab
- Efficacy of Rituximab for Remission Maintenance in Patients With Primary Angiitis of the Central Nervous System: an Open-label, Randomized, Controlled Trial Comparing Systematic Rituximab Infusions and AzathioprineNot yet recruitingPhase 2Centre Hospitalier St AnneNCT07902492Written as RUXIENCE®.
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingPhase 4IsalaNCT06031233Written as Rituximab
- Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)RecruitingPhase 2National Cancer Institute (NCI)NCT01419561Written as Rituximab
- Rituximab Plus Cyclosporine in Idiopathic Membranous NephropathyRecruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00977977Written as Rituximab Infusion
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingPhase 3BeOne MedicinesNCT06943872Written as Rituximab
- The HIt HArd and hiT Early in Multiple Sclerosis TrialRecruitingPhase 2Uppsala UniversityNCT07517185Written as Sequential treatment with rituximab and cladribine
- Pembrolizumab, Ibrutinib and Rituximab in PCNSLRecruitingPhase 1/2Dana-Farber Cancer InstituteNCT04421560Written as Rituximab
- Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingPhase 2University of WashingtonNCT07097363Written as Rituximab
- Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary FibrosisNot yet recruitingPhase 2University of Alabama at BirminghamNCT07674745Written as Rituximab
- Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse EventsRecruitingPhase 1Inge Marie SvaneNCT07694414Written as Rituximab (RTX)
See all 1,283 studies that test Rituximab →
Given beside what is tested · 589 — Rituximab is usual care or a partner of the new treatment
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)RecruitingPhase 2Merck Sharp & Dohme LLCNCT06890884Written as Rituximab
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06717347Written as Rituximab
- A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT07634471Written as Rituximab
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04840602Written as Rituximab
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04002947Written as Rituximab
- Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)RecruitingPhase 1/2University of UtahNCT07573436Written as Rituximab or rituximab biosimilar
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaNot yet recruitingPhase 1National Cancer Institute (NCI)NCT07444710Written as Rituximab
- The CARDIOPROTECT TrialNot yet recruitingPhase 2Beth Israel Deaconess Medical CenterNCT07654426Written as Rituximab
- Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS LymphomaRecruitingPhase 2Canadian Cancer Trials GroupNCT05998642Written as Rituximab (where available)
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic LeukemiaRecruitingPhase 1Hoffmann-La RocheNCT05091424Written as Rituximab
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Hoffmann-La RocheNCT05533775Written as Rituximab
- AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")RecruitingPhase 1National Cancer Institute (NCI)NCT07649304Written as Rituximab
- A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaRecruitingPhase 2Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07015242Written as Rituximab
- A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersRecruitingPhase 1Eli Lilly and CompanyNCT07226843Written as Rituximab
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT05976763Written as Rituximab
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)RecruitingPhase 2/3Merck Sharp & Dohme LLCNCT05139017Written as Rituximab
- Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic LeukemiaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT03150693Written as Rituximab
- Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesRecruitingPhase 1/2Nurix Therapeutics, Inc.NCT07520006Written as rituximab
- A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid MalignanciesRecruitingPhase 1Janssen Research & Development, LLCNCT07308132Written as Rituximab
- A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5Not yet recruitingPhase 3AstraZenecaNCT07911553Written as Rituximab
Showing 20 of 589.
As the comparator · 102 — what is tested is compared with Rituximab
- A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsRecruitingPhase 3BeOne MedicinesNCT06846671Written as Rituximab
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091254Written as Rituximab
- A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).RecruitingPhase 3Merck Sharp & Dohme LLCNCT05947851Written as Rituximab
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Not yet recruitingPhase 2/3Merck Sharp & Dohme LLCNCT07917754Written as Rituximab
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3Hoffmann-La RocheNCT06084936Written as Rituximab
- A Prospective, Open-label, Randomized, Multicenter Phase-III Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter TransformationRecruitingPhase 2German CLL Study GroupNCT07917780Written as Rituximab
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091865Written as Rituximab
- IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)RecruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT07104032Written as Rituximab
- Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05886036Written as Rituximab
- A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT07808827Written as Rituximab in combination with gemcitabine and oxaliplatin
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDRecruitingPhase 4Massachusetts General HospitalNCT07010302Written as Rituximab (R)
- A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06561360Written as Rituximab
- Evaluation of Iopofosine I 131 vs. R-CD in WM PatientsNot yet recruitingPhase 3Cellectar Biosciences, Inc.NCT07766421Written as Rituximab (active comparator)
- A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaRecruitingPhase 3Sinocelltech Ltd.NCT07562022Written as Rituximab
- A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell LymphomaRecruitingPhase 3Sinocelltech Ltd.NCT07570823Written as Rituxumab
- A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Not yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07753369Written as Rituximab injection
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingPhase 3Ascentage Pharma Group Inc.NCT06319456Written as Rituximab
- HDM2005 Combination Therapy in Relapsed/Refractory Mantle Cell LymphomaNot yet recruitingPhase 1Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.NCT07697339Written as Rituximab plus lenalidomide
- A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous NephropathyRecruitingPhase 3Cerium Pharmaceuticals, Inc.NCT05696613Written as Rituximab
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaRecruitingPhase 3The Lymphoma Academic Research OrganisationNCT06006117Written as Rituximab (R)
Showing 20 of 102.
What changed recently
From the registry's own updates since Oct 15, 2026.
Started recruiting2
- Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse EventsOct 20, 2026NCT07694414
- Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular LymphomaOct 15, 2026NCT07731789
Stopped1
- Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-DiseaseSuspendedOct 16, 2026NCT06046248
Newly registered3
- Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective StudyNov 2, 2026NCT07908888
- Efficacy of Rituximab for Remission Maintenance in Patients With Primary Angiitis of the Central Nervous System: an Open-label, Randomized, Controlled Trial Comparing Systematic Rituximab Infusions and AzathioprineOct 29, 2026NCT07902492
- Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCLOct 20, 2026NCT07884708
Codes
What other systems call Rituximab · ClinicalTrials.gg INT006567
- MeSH (NLM) D000069283RituximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 4F4X42SYQ6RITUXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 121191Confirmed FDA, Wikidata
- Wikidata Q412323rituximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1702RituximabOne source FDA
- DrugBank DB00073One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069283 | Rituximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 4F4X42SYQ6 | RITUXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 121191 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412323 | rituximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1702 | Rituximab | One source FDA |
| DrugBank | DB00073 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.